Oxford Biodynamics

15 articles about Oxford Biodynamics

• Oxford BioDynamics’ Prostate Screening EpiSwitch® Blood Test Significantly Enhances Overall Detection Accuracy For At Risk Men

  2/6/2023

  Oxford BioDynamics, Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform, announces the publication of compelling results involving OBD’s technology in the multi-disciplinary PROSTAGRAM study using blood to detect prostate cancer in an at risk population. These results were referred to in the recent results statement.

• Oxford BioDynamics in San Francisco for the 41st Annual J.P. Morgan Healthcare Conference

  12/19/2022

  Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for immune health based on the EpiSwitch ® 3D genomics platform, announced that its senior leadership will be in San Francisco during the 41st Annual J.P. Morgan Healthcare Conference, Jan 9-12 2023.

• Massachusetts General Hospital Reports Results of Interim Analysis from REFINE-ALS Biomarker Trial by Mitsubishi Tanabe Pharma USA, Utilizing Oxford Biodynamics’ EpiSwitch® Platform for Prognostic Stratification of Fast Progression ALS

  12/16/2022

  Oxford BioDynamics, Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for immune health based on the EpiSwitch® 3D genomics platform, announces the initial results from an interim analysis conducted for the REFINE-ALS prospective trial.

• Prominent oncologist to discuss advantages of Oxford BioDynamics’ EpiSwitch CiRT at the 2022 Liquid Biopsy Virtual Summit

  11/21/2022

  Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for immune health based on the EpiSwitch 3D genomics platform, announces that prominent medical oncologist, Dr. Steven Mamus, a regular user of EpiSwitch CiRT, will be speaking about OBD’s flagship test at the 2022 Liquid Biopsy Virtual Summit, 6 December 2022.

• Oxford BioDynamics Awarded US FNIH Grant to Apply EpiSwitch® Immune Health Test for Improved Prediction of Patient Response to Immune Checkpoint Inhibitor (ICI) Cancer Therapies

  8/31/2021

  Oxford BioDynamics announces that it has been awarded an FNIH Partnership for Accelerating Cancer Therapies (PACT) Grant to use the EpiSwitch diagnostic platform for accurate prediction of a patient’s response to Immune Checkpoint Inhibitors (ICIs) from a routine blood sample.

• The Prime Meridian Group Collaborates With Oxford BioDynamics Plc On Market Research

  5/18/2021

  The Prime Meridian Group is providing Oxford BioDynamics Plc, a biotechnology company focused on the discovery and development of 3D genomic biomarkers for use within the pharmaceutical and biotechnology industry, assistance with market research related to the testing for the award-winning, proprietary technology platform, EpiSwitch™.

•  Oxford BioDynamics signs supply and resale agreement with Agilent Technologies, and launches EpiSwitch® Explorer Array Kit for R&D use

  3/31/2021

  Launch of the EpiSwitch® Explorer Array Kit expands academic and clinical researcher access to OBD’s EpiSwitch® technology platform following the launch of its EpiSwitch®CST (COVID-19 Severity Test)

• Oxford BioDynamics announces US launch of its EpiSwitch® COVID-19 Severity Test (CST)

  3/23/2021

  EpiSwitch® CST is a highly accurate prognostic test that predicts personalized risk of severe illness due to SARS-CoV-2 virus

• Oxford BioDynamics Announces Strategic Partnership with Boca Biolistics in Order to Advance EpiSwitch™ Disease Severity Program for COVID-19

  11/2/2020

  Highly diverse samples will enable development of world’s first 3D genomics prognostic immune health test for disease severity

• 

  BioSpace Global Roundup, Oct. 29

  10/29/2020

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

• Oxford BioDynamics Advances EpiSwitch™ Disease Severity Program for COVID-19 with Top US Academic Health Center, Oregon Health & Science University

  10/28/2020

  Expertly annotated patient samples from world-class clinical research facility Samples used to advance development of the world’s first 3D genomic severity test for COVID-19 disease built using the EpiSwitch™ platform Goal is to provide insight into a wide range of COVID-19 responses, from mild to severe Adds to Oxford BioDynamics’ growing bank of 500+ procured samples from cohorts around the world

• Oxford BioDynamics' EpiSwitch™ Featured in Presentations on Development and Validation of Blood-Based Predictive Biomarkers in Immune Checkpoint Inhibitor Programs

  11/8/2019

  Oxford BioDynamics Plc (AIM: OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers for the pharmaceutical and biotechnology industry, today announced that data yielded by application of its 3D genome architecture technology platform, EpiSwitch™, will be presented at The Society for Immunotherapy of Cancer's 34th Annual Meeting.

• Oxford BioDynamics Joins ALS Biomarker Study Sponsored By Mitsubishi Tanabe Pharma America

  5/3/2019

  Proprietary Technology Platform to Assess Biomarker Panels in People with ALS

• Oxford Biodynamics Presents At The Diabetes Asia 2017 Conference

  10/13/2017

• Oxford Biodynamics Presents Applications Of Its Epigenetic Biomarker Technology EpiSwitch At The Annual Meeting Of The American Society of Hematology In San Diego

  12/12/2016